Cellectar Biosciences Inc (CLRB)
3.325
-0.18
(-5.27%)
USD |
NASDAQ |
Apr 15, 16:00
3.32
0.00 (0.00%)
After-Hours: 20:00
Cellectar Biosciences Enterprise Value: 103.76M for April 15, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 15, 2024 | 103.76M |
| April 12, 2024 | 109.73M |
| April 11, 2024 | 116.18M |
| April 10, 2024 | 109.08M |
| April 09, 2024 | 116.83M |
| April 08, 2024 | 119.41M |
| April 05, 2024 | 117.79M |
| April 04, 2024 | 116.50M |
| April 03, 2024 | 124.89M |
| April 02, 2024 | 125.21M |
| April 01, 2024 | 122.96M |
| March 28, 2024 | 124.89M |
| March 27, 2024 | 113.76M |
| March 26, 2024 | 120.70M |
| March 25, 2024 | 121.34M |
| March 22, 2024 | 127.15M |
| March 21, 2024 | 121.34M |
| March 20, 2024 | 73.87M |
| March 19, 2024 | 74.91M |
| March 18, 2024 | 65.99M |
| March 15, 2024 | 68.68M |
| March 14, 2024 | 66.61M |
| March 13, 2024 | 69.93M |
| March 12, 2024 | 71.80M |
| March 11, 2024 | 74.70M |
| Date | Value |
|---|---|
| March 08, 2024 | 79.47M |
| March 07, 2024 | 80.92M |
| March 06, 2024 | 79.47M |
| March 05, 2024 | 80.51M |
| March 04, 2024 | 84.45M |
| March 01, 2024 | 83.62M |
| February 29, 2024 | 77.81M |
| February 28, 2024 | 78.23M |
| February 27, 2024 | 76.98M |
| February 26, 2024 | 68.89M |
| February 23, 2024 | 65.78M |
| February 22, 2024 | 65.99M |
| February 21, 2024 | 64.43M |
| February 20, 2024 | 64.74M |
| February 16, 2024 | 67.96M |
| February 15, 2024 | 70.97M |
| February 14, 2024 | 69.10M |
| February 13, 2024 | 66.82M |
| February 12, 2024 | 69.10M |
| February 09, 2024 | 69.10M |
| February 08, 2024 | 69.31M |
| February 07, 2024 | 69.72M |
| February 06, 2024 | 70.14M |
| February 05, 2024 | 67.44M |
| February 02, 2024 | 74.49M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-7.867M
Minimum
May 12 2022
127.15M
Maximum
Mar 22 2024
16.46M
Average
9.825M
Median
Enterprise Value Benchmarks
| Perspective Therapeutics Inc | 890.47M |
| Eli Lilly and Co | 736.20B |
| Actinium Pharmaceuticals Inc | 171.43M |
| Bristol-Myers Squibb Co | 125.64B |
| Altimmune Inc | 337.44M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.449M |
| Total Expenses (Quarterly) | 12.55M |
| EPS Diluted (Quarterly) | -0.40 |
| Earnings Yield | -93.23% |